Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + Capecitabine vs Cetuximab Maintenance in mCRC
NCT04262635Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Maintenance Progression-Free Survival. Status: unknown.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04262635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262635.